EIF5A2 Monoclonal antibody
EIF5A2 Monoclonal Antibody for WB, IHC, IF/ICC, ELISA
Host / Isotype
Mouse / IgG1
Reactivity
Human, rat
Applications
WB, IHC, IF/ICC, ELISA
Conjugate
Unconjugated
CloneNo.
1F9B2
Cat no : 67907-1-Ig
Synonyms
Validation Data Gallery
Tested Applications
Positive WB detected in | HeLa cells, HEK-293 cells, Jurkat cells, K-562 cells, HSC-T6 cells |
Positive IHC detected in | human lung cancer tissue, human stomach cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Positive IF/ICC detected in | HepG2 cells |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:5000-1:50000 |
Immunohistochemistry (IHC) | IHC : 1:500-1:2000 |
Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Product Information
67907-1-Ig targets EIF5A2 in WB, IHC, IF/ICC, ELISA applications and shows reactivity with Human, rat samples.
Tested Reactivity | Human, rat |
Host / Isotype | Mouse / IgG1 |
Class | Monoclonal |
Type | Antibody |
Immunogen | EIF5A2 fusion protein Ag10852 相同性解析による交差性が予測される生物種 |
Full Name | eukaryotic translation initiation factor 5A2 |
Calculated molecular weight | 153 aa, 17 kDa |
Observed molecular weight | 20 kDa |
GenBank accession number | BC036072 |
Gene symbol | EIF5A2 |
Gene ID (NCBI) | 56648 |
RRID | AB_2918663 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Protein G purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Eukaryotic translation initiation factor 5A (EIF5A), a conserved lysine to hypusine, is strictly indispensable for the survival of eukaryotic cells. There are two EIF5A isoforms in humans: EIF5A1 and EIF5A2. EIF5A2 has been reported to be overexpressed in gallbladder cancer, upper urinary tract urothelial carcinoma, gastric cancer, prostate cancer, nasopharyngeal carcinoma, and cervical cancer. EIF5A2 upregulation in cancer tissues is associated with poor prognosis in these patients.
Protocols
Product Specific Protocols | |
---|---|
WB protocol for EIF5A2 antibody 67907-1-Ig | Download protocol |
IHC protocol for EIF5A2 antibody 67907-1-Ig | Download protocol |
IF protocol for EIF5A2 antibody 67907-1-Ig | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |